Unusual Skin Lesions in a Patient with Diarrhea

  • Scott Miller
  • Fred Thomas
Part of the Contemporary Internal Medicine book series (COIM, volume 3)


According to Thomas Jefferson, “The disorders of the human body and the exanthems indicating them are as various as the elements of which it is composed.” Nowhere in medicine is this more true than in diseases of the gastrointestinal tract. Diseases of the skin and gastrointestinal tract do not necessarily occur together by mere coincidence. Rather, they may be manifestations of the same entity, or may occur as a consequence of one another. It is an irony of our medical era that, in spite of the fact that the skin is the most observable, readily accessible, easily invadable “window” to the body, physicians frequently fail to see the clues it provides to gastrointestinal diseases. Indeed, the following case illustrates how nearsighted we are in this respect, for rather than providing a reflection of the patient’s underlying disease, her skin lesions only served as a draperylike barrier to those initially caring for her.


Inflammatory Bowel Disease Ulcerative Colitis Primary Sclerosing Cholangitis Pyoderma Gangrenosum Extraintestinal Manifestation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jorizzo JC, Soloman AR, Zanelli MD, et al: Neutrophilic vascular reactions. JAAD. 1988;19:983–1005.CrossRefGoogle Scholar
  2. 2.
    Su WPD, Liu HNH: Diagnostic criteria for Sweet’s syndrome. Int J Dermatol. 1987;26:178–180.CrossRefGoogle Scholar
  3. 3.
    Jozzio JC: Bechet’s disease: An update based on the 1985 international conference in London. Arch Dermatol. 1986;122:556–558.CrossRefGoogle Scholar
  4. 4.
    Brachman PS: Anthrax, in Evans A, Feldman H (eds): Bacterial Infections of Humans: Epidemiology and Control. New York, Plenum Medical Book Co, 1982, pp 63–74.CrossRefGoogle Scholar
  5. 5.
    Boudoulas O, Siegle RJ, Grimwood RE: Ioderma occurring after orally administered iopanoic acid. Arch Dermatol. 1987;123:387–388.PubMedCrossRefGoogle Scholar
  6. 6.
    Hideman JG: Pyoderma gangrenosum. Clin Dermatol. 1983;1:102–113.CrossRefGoogle Scholar
  7. 7.
    Greenstein AJ, Janowitz HO, Sachar DB: The extra-intestinal complications of Crohn’s disease and ulcerative colitis: A study of 700 patients. Medicine. 1976;55:401.PubMedCrossRefGoogle Scholar
  8. 8.
    McCallum DI, Kinmono PDC: Dermatologie manifestations of Crohn’s disease. Br J Dermatol. 1968;80:1.PubMedCrossRefGoogle Scholar
  9. 9.
    Edwards FC, Truelove SC: The course and prognosis of ulcerative colitis. Gut. 1964;5:1.PubMedCrossRefGoogle Scholar
  10. 10.
    Croft CB, Wilkinson AR: Ulceration of the mouth, pharynx, and larynx in Crohn’s disease of the intestine. Br J Surg. 1972;59:249.PubMedCrossRefGoogle Scholar
  11. 11.
    Schacter H, Kirsner J: Definitions of inflammatory bowel disease of unknown etiology. Gastroenterology. 1975;68:591.Google Scholar
  12. 12.
    Donaldson RM Jr: Crohn’s disease, in Sleisenger MH, Fordtran JS (eds): Gastrointestinal Disease, Philadelphia, 4 ed. WB Saunders Co, 1989.Google Scholar
  13. 13.
    Wright R, Lunsden J, Luntz MH, et al: Abnormalities of the sacroiliac joints and uveitis. QJ Med. 1965;34:229–236.PubMedGoogle Scholar
  14. 14.
    Rankin GB, Watts HD, Melynk CS, et al: The National Cooperative Crohn’s Disease Study: Extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77:914–920.PubMedGoogle Scholar
  15. 15.
    Danzi JT: Extraintestinal manifestations of idiopathic inflammatory bowel disease. Arch Intern Med. 1988;148:297–302.PubMedCrossRefGoogle Scholar
  16. 16.
    Moll JM: Inflammatory bowel disease, in Pancyi GS (ed): Clinics in Rheumatic Disease. Philadelphia, WB Saunders Co, 1985, pp 87–105.Google Scholar
  17. 17.
    Neuman V, Wright V: Arthritis associated with inflammatory bowel disease. in Losowsky MS (ed): Clinics in Rheumatic Disease. Philadelphia, WB Saunders Co, 1983, pp 767–795.Google Scholar
  18. 18.
    Talbot RW, Helppell J, Dozios RR, et al: Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140–145.PubMedCrossRefGoogle Scholar
  19. 19.
    Conlan MG, Haise WD, Burnett DA: Prothrombotic abnormalities in inflammatory bowel disease. Dig Dis Sci. 1989;7:1089–1093.CrossRefGoogle Scholar
  20. 20.
    Wee A, Ludwig J: Pericholangitis in chronic ulcerative colitis: Primary sclerosing cholangitis of the small bile ducts. Ann Intern Med. 1985;102:581–587.PubMedCrossRefGoogle Scholar
  21. 21.
    Kyle J: Urinary complications of Crohn’s disease. World J Surg. 1980;4:153–160.PubMedCrossRefGoogle Scholar
  22. 22.
    Summers RW, Switz DM, Sessions JT, et al: National Cooperative Crohn’s Disease Study: Results of drug treatment. Gastroenterology. 1979;77:847–869.PubMedGoogle Scholar
  23. 23.
    Hawkey CJ, Boughter-Smith NK, Whittle BJR: Modulation of human colonie arachidonic acid metabolism by sulfasalazine. Dig Dis Sci. 1985;30:1161–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Dreyling KW, Hoppe V, Peskar BH, et al: Leukotrienes in Crohn’s disease: Effect of sulfasalazine and 5-aminosalicylic acid. Adv Prostaglandin Thromboxane Leukotriene Res. 1987;17:339–343.Google Scholar
  25. 25.
    Das K: Sulfasalazine therapy in inflammatory bowel disease. Gastroenterol Clin North Am. March 1989.Google Scholar
  26. 26.
    Ginsberg AL: Topical salicylate therapy (4-ASA and 5-ASA enemas). Gastroenterol Clin North Am. March 1989.Google Scholar
  27. 27.
    Jewell DP: Corticosteroids for the management of ulcerative colitis and Crohn’s disease. Gastroenterol Clin North Am. March 1989.Google Scholar
  28. 28.
    Robinson M: New Oral Salicylates in the therapy of chronic idiopathic inflammatory bowel disease. Gastroenterol Clin North Am. March 1989.Google Scholar
  29. 29.
    Brandt LJ, Bernstein LH, Boley SJ, et al: Metronidazole therapy for perianal Crohn’s disease: A follow-up study. Gastroenterology. 1982;23:383–387.Google Scholar
  30. 30.
    Present DH: 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn’s disease and ulcerative colitis. Gastroenterol Clin of North Am. March 1989.Google Scholar
  31. 31.
    Present DH, Meltzer SJ, Krumholz MP, et al: 6-Mercaptopurine in the management of inflammatory bowel disease: Short-and long-term toxicity. Ann Intern Med. 1989;111:641–649.PubMedCrossRefGoogle Scholar
  32. 32.
    Brynshov J, Freund L, Rosmussensiv, et al: A placebo controlled, double-blind, randomized trial of cyclosporin therapy in active chronic Crohn’s disease. N Engl J Med. 1989;321:845–850.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Scott Miller
  • Fred Thomas

There are no affiliations available

Personalised recommendations